TMOThermo Fisher Scientific
Is it safe?
Strong, no red flags: a safe balance sheet.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Insiders were net sellers (-$61.6M, 90 days to Oct 8, 2026), selling is often routine.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Moderate price swings, typical volatility. Worst drawdown -41% · now 3% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can TMO take a bad year?
Thermo Fisher Scientific carries $38.5B of net debt at 4.14× EBITDA: a heavy load to carry through a bad year.
Net debt · as at Q2 2026 · over four years of earnings before interest, tax and depreciation, heavy
- Net debt / EBITDA
- 4.14×
Net debt / EBITDA · 3.38× a year ago · the load is going up
- Altman Z-score
- 3.35
Altman Z-score · safe zone, above 3
- Interest cover
- 5.55×
Interest cover · operating profit covers the interest bill several times over
Details›
- Total debtQ2 2026
- $42.5B
- Cash and short-term investments
- $4.06B
- Net debt
- $38.5B
- EBITDA, trailing twelve months
- $9.30B
- Operating profit, trailing twelve months
- $8.15B
- Debt / equity
- 0.81×
- Total debt / EBITDA
- 4.57×
- Annualised volatilitytwo years of daily moves
- 31%
- Worst drawdown on file
- −41%
- Below its 52-week high
- 3.3%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Diagnostics & Research
The closest names by size in the same industry